OCHIX
Price
$8.92
Change
+$0.08 (+0.90%)
Updated
Aug 5 closing price
Net Assets
47.05M
TRCLX
Price
$12.22
Change
+$0.05 (+0.41%)
Updated
Aug 5 closing price
Net Assets
51.53M
Interact to see
Advertisement

OCHIX vs TRCLX

Header iconOCHIX vs TRCLX Comparison
Open Charts OCHIX vs TRCLXBanner chart's image
Oberweis China Opportunities Instl
Price$8.92
Change+$0.08 (+0.90%)
VolumeN/A
Net Assets47.05M
T. Rowe Price China Evolution Equity I
Price$12.22
Change+$0.05 (+0.41%)
VolumeN/A
Net Assets51.53M
OCHIX vs TRCLX Comparison Chart in %
Loading...
View a ticker or compare two or three
Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
TRCLX has more cash in the bank: 51.5M vs. OCHIX (47.1M). OCHIX pays higher dividends than TRCLX: OCHIX (1.90) vs TRCLX (1.56). OCHIX was incepted earlier than TRCLX: OCHIX (8 years) vs TRCLX (6 years). TRCLX (2.10) is less costly to investors than OCHIX (1.92). OCHIX is a more actively managed with annual turnover of: 155.00 vs. TRCLX (82.40). TRCLX has a lower initial minimum investment than OCHIX: TRCLX (500000) vs OCHIX (1000000). OCHIX annual gain was more profitable for investors over the last year : 39.08 vs. TRCLX (28.06). TRCLX return over 5 years is better than : -12.87 vs. OCHIX (-48.22).
OCHIXTRCLXOCHIX / TRCLX
Total Expense Ratio1.921.03186%
Annual Report Gross Expense Ratio1.922.1091%
Fund Existence8 years6 years-
Gain YTD23.25213.636171%
Front LoadN/AN/A-
Min. Initial Investment1000000500000200%
Min. Initial Investment IRAN/AN/A-
Net Assets47.1M51.5M91%
Annual Yield % from dividends1.901.56122%
Returns for 1 year39.0828.06139%
Returns for 3 years5.963.84155%
Returns for 5 years-48.22-12.87375%
Returns for 10 yearsN/AN/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UNBX0.060.01
+9.27%
Unity Biotechnology, Inc.
MFGHF39.60N/A
N/A
Mainfreight Ltd.
MSADF22.89N/A
N/A
MS&AD Insurance Group Holdings, Inc.
PLRRF6.40N/A
N/A
Polar Capital Holdings PLC
PVCT0.09N/A
-0.54%
Provectus Biopharmaceuticals, Inc.